The Transparency Board will evaluate medications for migraine and lymphoma

The agenda includes:
Preparation of positions on the evaluation of the drug Emgality (galcanezumabum) under the drug program: "Prophylactic treatment of patients with chronic migraine (ICD-10: G43)".
Preparation of an opinion on the reimbursement of drugs containing the active substance oxaliplatinum in the following indications:
• C81 Malignant Hodgkin's disease [Hodgkin's disease] (C.81.0 Lymphocyte predominance; C.81.1 Nodular sclerosis; C.81.2 Mixed cell form; C.81.3 Lymphocyte atrophy; C.81.7 Other malignant Hodgkin's disease; C.81.9 Malignant Hodgkin, unspecified);
• C82 Nodular [Follicular] non-Hodgkin's lymphoma (C82.0 Small-cell lymphoma nodular, nodular; C82.1 Mixed small-cell nodular and large-cell, nodular; C82.2 Large-cell, nodular; C82.3 Large-cell nodular; C82.7 Other types of nodular non-Hodgkin's lymphoma; C82.9 Nodular non-Hodgkin's lymphoma, unspecified);
• C83 Diffuse non-Hodgkin's lymphoma (83.0 Small cells (diffuse); 83.1 Small cells with convex nucleus (diffuse); 83.2 Mixed small and large cells (diffuse); C83.3 Large B-cell lymphoma - DLBCL; 83.4 Immunoblastic ( diffuse); 83.5 Lymphoblastic (diffuse); 83.6 Undifferentiated (diffuse); 83.7 Burkitt's tumor; 83.9 Diffuse non-Hodgkin's lymphoma, unspecified);
• C84 Peripheral and cutaneous T cell lymphoma (C84.0 Mycosis fungoides; C84.1 Sézary's disease; C84.2 T zone lymphoma; C84.3 Lymphoepithelioma; C84.4 Peripheral T cell lymphoma; C84.5 Others and unspecified T-cell lymphomas);
• C85 Other and unspecified forms of non-Hodgkin's lymphoma (C85.0 Lymphosarcoma; C85.1 B-cell lymphoma, unspecified; C85.7 Other specified types of non-Hodgkin's lymphoma a) Malignant: reticulitis, retinitis b) Microglioma; C85.9 Non-Hodgkin's lymphoma, unspecified (Lymphoma BNO, Malignant lymphoma BNO, Non-Hodgkin's lymphoma NOS);
• C88.0 Waldenström's macroglobulinemia and C88.4 MALT lymphoma;
• C22 Malignant neoplasm of the liver and intrahepatic bile ducts [Excludes: biliary tract NOS (C24.9) secondary malignant neoplasm of the liver (C78.7)] (C22.1 Cancer of intrahepatic bile duct Cholangiocarcinoma);
• C23 Malignant neoplasm of the gallbladder;
• C24 Malignant neoplasm of other and unspecified parts of the bile ducts (C24.0 Extrahepatic bile ducts (BNO bile ducts BNO Common bile duct Cystic duct Common hepatic duct); C24.1 Vater duodenal major papilla; C24.8 Overlapping lesion of one location within the tract biliary; C24.9 Biliary tract, location unspecified).
Preparation of opinions on draft health policy programs of local government units:
• "Health Policy Program of the Ełk Commune for 2022-2026 in the field of prevention and early detection of type 2 diabetes",
• "Health Policy Program of the Ełk Commune for 2022-2026 in the field of prevention of breast and mammary gland diseases".

Source: AOTMiT